Key result
Stopping anticoagulation for isolated subsegmental pulmonary embolism could not be evaluated for clinical efficacy because the trial was stopped prematurely due to low recruitment.
Why the study?
Increasing CT pulmonary angiography use has led to more diagnoses of small subsegmental pulmonary embolism, raising concerns of over-diagnosis and clinical equipoise regarding the value of full anticoagulation versus bleeding risks.
Population
Patients diagnosed with isolated subsegmental pulmonary embolism without leg vein thrombus
Comparison
Stopping anticoagulation completely vs continuing at least 3 months of full-dose anticoagulation
Design
Open randomised trial with blinded end-point adjudication
Authors
Loading...
Leaves open safety of withholding anticoagulation for isolated subsegmental PE; further RCTs needed before practice change.
RCT
Open-label
Randomized
Yes
Lasserson et al. (2025) conducted an RCT in Isolated subsegmental pulmonary embolism. Stopping anticoagulation vs. Continuing with at least 3 months of full-dose anticoagulation was evaluated. Stopping anticoagulation for isolated subsegmental pulmonary embolism could not be evaluated for clinical efficacy because the trial was stopped prematurely due to low recruitment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: